Suggested remit: To appraise the clinical and cost effectiveness of acalabrutinib with bendamustine and rituximab within its marketing authorisation for untreated mantle cell lymphoma.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6155

Provisional Schedule

Committee meeting 11 June 2025
Expected publication 20 August 2025

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Stakeholders

Companies sponsors AstraZeneca (acalabrutinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  DKMS
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Kevin Karawa Leukaemia Trust
  Leukaemia Cancer Society
  Leukaemia Care
  Leukaemia UK
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  WMUK
Professional groups Association of Cancer Physicians
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society for Haematology
  British Society of Interventional Radiology
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
  United Kingdom Cutaneous Lymphoma Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord-UK Ltd (bendamustine)
  Aspire Pharma (bortezomib)
  Aurobindo Pharma (bortezomib)
  Baxter Healthcare Ltd (cyclophosphamide, doxorubicin)
  Biotech Pharma (bortezomib)
  Celltrion Healthcare UK Ltd (rituximab)
  Dr Reddy’s Laboratories UK Ltd (bendamustine, bortezomib)
  Hospira UK Ltd (cytarabine, vincristine)
  Jazz Pharmaceuticals UK (cytarabine)
  Johnson & Johnson Ltd (bortezomib)
  medac GmbH (bortezomib, doxorubicin)
  MSN Laboratories Europe (bortezomib)
  Mylan (bortezomib)
  Pfizer Ltd (bortezomib, doxorubicin, rituximab)
  Roche Products Ltd (rituximab)
  Sandoz Ltd (bortezomib, cyclophosphamide, rituximab)
  Seacross Pharmaceuticals Ltd (bendamustine, doxorubicin)
  Sun Pharma (bortezomib)
  Thornton & Ross Ltd (bortezomib)
  Tillomed Laboratories Ltd (bortezomib)
  Zentiva Pharma Ltd (bendamustine)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  Lymphoma Research Trust
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
24 September 2024 Invitation to participate
23 July 2024 - 20 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6155
23 July 2024 In progress. Scoping commenced.
25 April 2023 As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Acalabrutinib with bendamustine and rituximab within its marketing authorisation for untreated mantle cell lymphoma [ID6155]. Please note that following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations.
11 July 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual